Ozempic Price Slashed in India Amid Generic Competition

As of April 1, 2026, Novo Nordisk has implemented a substantial price reduction for its popular diabetes and weight-loss medications, Ozempic and Wegovy, in India. The lowest weekly dosage will now be priced at ₹1,415, a significant decrease from previous costs ranging from ₹2,200 to ₹2,712.

This price adjustment was made shortly after the expiration of the Indian patent for semaglutide, the active ingredient in these drugs, on March 21, 2026. This patent expiry has allowed domestic pharmaceutical companies, such as Dr. Reddy's and Sun Pharma, to introduce generic versions at a considerably lower cost, up to a 70% discount.

Novo Nordisk's managing director in India stated that the price revision aims to enhance affordability for cardio-metabolic care. The company acknowledges the substantial burden of diabetes and obesity in India and seeks to make its treatments more accessible to a wider population.

The competitive landscape in India is intensifying, with rivals like Eli Lilly also making aggressive moves. Lilly's drug Mounjaro quickly became a top-selling medication by value following its launch last year. Industry analysts suggest that while generic versions offer a significant discount, Novo Nordisk's established brand loyalty and safety data may persuade some patients to opt for the original medication, especially if the price difference remains within a certain margin.

This pricing strategy reflects a broader pharmaceutical trend of prioritizing volume over margins in emerging markets. With India's rising rates of obesity and a diabetic population exceeding 100 million, securing a large patient base is crucial for sustained market dominance. The new daily cost of approximately ₹202 is expected to help Novo Nordisk defend its market share against generic competition.